VTv Therapeutics Posts Wider FY25 Loss, Advances Phase 3 CATT1 Trial For Type 1 Diabetes

vTv Therapeutics reported fourth-quarter and full-year 2025 results and emphasized continued progress in its late-stage diabetes pipeline, led by Cadisegliatin, an oral, liver-selective glucokinase activator. The announcement focused on program updates rather than detailed financial metrics; clinical or regulatory progress on Cadisegliatin is the primary driver that could modestly move the stock pending future milestones.

Analysis

vTv Therapeutics reported fourth-quarter and full-year 2025 results and emphasized continued progress in its late-stage diabetes pipeline, led by Cadisegliatin, an oral, liver-selective glucokinase activator. The announcement focused on program updates rather than detailed financial metrics; clinical or regulatory progress on Cadisegliatin is the primary driver that could modestly move the stock pending future milestones.